Cargando…

Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B

Ghrelin is an endogenous ligand of growth hormone (GH) secretagogue receptor (GHSR) and has a number of biological effects, including heart protection. The present study aimed to reveal the positive effect of ghrelin on myocardium with hypoxia/reoxygenation (H/R) treatment and the involved molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Liu, Yanling, Li, Guolin, Chen, Zhengrong, Gu, Guixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202102/
https://www.ncbi.nlm.nih.gov/pubmed/30272367
http://dx.doi.org/10.3892/ijmm.2018.3886
_version_ 1783365638476005376
author Liu, Yang
Liu, Yanling
Li, Guolin
Chen, Zhengrong
Gu, Guixiong
author_facet Liu, Yang
Liu, Yanling
Li, Guolin
Chen, Zhengrong
Gu, Guixiong
author_sort Liu, Yang
collection PubMed
description Ghrelin is an endogenous ligand of growth hormone (GH) secretagogue receptor (GHSR) and has a number of biological effects, including heart protection. The present study aimed to reveal the positive effect of ghrelin on myocardium with hypoxia/reoxygenation (H/R) treatment and the involved molecular mechanisms. Successful construction of lentiviral expression vector (ghrelin-pLVX-Puro) was confirmed by colony polymerase chain reaction (PCR) verification. Primary rat cardiac myocytes were isolated and identified by immunofluorescence staining. Existence of red fluorescence of α-sarcomeric actinin indicated the successful isolation. Following ghrelin transfection and H/R treatment, primary cells were divided into four groups: Control, H/R, empty (empty pLVX-Puro + H/R) and ghrelin (ghrelin-pLVX-Puro + H/R). Cell viability and apoptosis were evaluated by Cell Counting Kit-8 (CCK-8) and Hoechst staining, respectively. The cell viability in the ghrelin group was significantly higher than that in the empty control group (P<0.05). The apoptosis rate in the ghrelin group was significantly lower than that in the empty control group (P<0.05). An ex vivo rat cardiac perfusion model was established. Following ghrelin incubation and H/R treatment, ex vivo myocardium was divided into four groups: Control, sham, H/R and ghrelin (ghrelin + H/R). Immunohistochemical analysis demonstrated that ghrelin increased the integrity of cardiac myocytes, and decreased shrinkage and apoptosis. mRNA and protein expression levels of GH, GHSR, insulin-like growth factor-1 (IGF-1), protein kinase B (Akt), phosphorylated Akt (p-Akt) were determined by reverse transcription (RT)-PCR, western blot analysis and immunohistochemical analysis. Ghrelin upregulated the mRNA and protein expression levels of GH, GHSR and IGF-1, and increased the ratio of p-Akt to Akt protein level (p-Akt/Akt) in cardiac myocytes and myocardial tissues with H/R treatment. In conclusion, ghrelin protected the myocardium with H/R treatment through upregulating the expression of GH, GHSR and IGF-1, and promoting the phosphorylation of Akt. This would provide promising insights into the treatment of hypoxic myocardial injury by ghrelin.
format Online
Article
Text
id pubmed-6202102
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-62021022018-11-07 Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B Liu, Yang Liu, Yanling Li, Guolin Chen, Zhengrong Gu, Guixiong Int J Mol Med Articles Ghrelin is an endogenous ligand of growth hormone (GH) secretagogue receptor (GHSR) and has a number of biological effects, including heart protection. The present study aimed to reveal the positive effect of ghrelin on myocardium with hypoxia/reoxygenation (H/R) treatment and the involved molecular mechanisms. Successful construction of lentiviral expression vector (ghrelin-pLVX-Puro) was confirmed by colony polymerase chain reaction (PCR) verification. Primary rat cardiac myocytes were isolated and identified by immunofluorescence staining. Existence of red fluorescence of α-sarcomeric actinin indicated the successful isolation. Following ghrelin transfection and H/R treatment, primary cells were divided into four groups: Control, H/R, empty (empty pLVX-Puro + H/R) and ghrelin (ghrelin-pLVX-Puro + H/R). Cell viability and apoptosis were evaluated by Cell Counting Kit-8 (CCK-8) and Hoechst staining, respectively. The cell viability in the ghrelin group was significantly higher than that in the empty control group (P<0.05). The apoptosis rate in the ghrelin group was significantly lower than that in the empty control group (P<0.05). An ex vivo rat cardiac perfusion model was established. Following ghrelin incubation and H/R treatment, ex vivo myocardium was divided into four groups: Control, sham, H/R and ghrelin (ghrelin + H/R). Immunohistochemical analysis demonstrated that ghrelin increased the integrity of cardiac myocytes, and decreased shrinkage and apoptosis. mRNA and protein expression levels of GH, GHSR, insulin-like growth factor-1 (IGF-1), protein kinase B (Akt), phosphorylated Akt (p-Akt) were determined by reverse transcription (RT)-PCR, western blot analysis and immunohistochemical analysis. Ghrelin upregulated the mRNA and protein expression levels of GH, GHSR and IGF-1, and increased the ratio of p-Akt to Akt protein level (p-Akt/Akt) in cardiac myocytes and myocardial tissues with H/R treatment. In conclusion, ghrelin protected the myocardium with H/R treatment through upregulating the expression of GH, GHSR and IGF-1, and promoting the phosphorylation of Akt. This would provide promising insights into the treatment of hypoxic myocardial injury by ghrelin. D.A. Spandidos 2018-12 2018-09-18 /pmc/articles/PMC6202102/ /pubmed/30272367 http://dx.doi.org/10.3892/ijmm.2018.3886 Text en Copyright: © Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Yang
Liu, Yanling
Li, Guolin
Chen, Zhengrong
Gu, Guixiong
Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
title Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
title_full Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
title_fullStr Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
title_full_unstemmed Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
title_short Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
title_sort ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase b
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202102/
https://www.ncbi.nlm.nih.gov/pubmed/30272367
http://dx.doi.org/10.3892/ijmm.2018.3886
work_keys_str_mv AT liuyang ghrelinprotectsthemyocardiumwithhypoxiareoxygenationtreatmentthroughupregulatingtheexpressionofgrowthhormonegrowthhormonesecretagoguereceptorandinsulinlikegrowthfactor1andpromotingthephosphorylationofproteinkinaseb
AT liuyanling ghrelinprotectsthemyocardiumwithhypoxiareoxygenationtreatmentthroughupregulatingtheexpressionofgrowthhormonegrowthhormonesecretagoguereceptorandinsulinlikegrowthfactor1andpromotingthephosphorylationofproteinkinaseb
AT liguolin ghrelinprotectsthemyocardiumwithhypoxiareoxygenationtreatmentthroughupregulatingtheexpressionofgrowthhormonegrowthhormonesecretagoguereceptorandinsulinlikegrowthfactor1andpromotingthephosphorylationofproteinkinaseb
AT chenzhengrong ghrelinprotectsthemyocardiumwithhypoxiareoxygenationtreatmentthroughupregulatingtheexpressionofgrowthhormonegrowthhormonesecretagoguereceptorandinsulinlikegrowthfactor1andpromotingthephosphorylationofproteinkinaseb
AT guguixiong ghrelinprotectsthemyocardiumwithhypoxiareoxygenationtreatmentthroughupregulatingtheexpressionofgrowthhormonegrowthhormonesecretagoguereceptorandinsulinlikegrowthfactor1andpromotingthephosphorylationofproteinkinaseb